PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
about
Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injuryThe Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisNewly characterized interaction stabilizes DNA structure: oligoethylene glycols stabilize G-quadruplexes CH-π interactions.Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Design and engineering of deimmunized biotherapeutics.Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.Recent advances in (therapeutic protein) drug development.Enhancing the therapeutic potential of peptide toxins.Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.BMP2-modified injectable hydrogel for osteogenic differentiation of human periodontal ligament stem cells.A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol.Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse AgonistChronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency.Magnetic Resonance and Ultrastructural Characterization of PEGylation-associated Vacuolation in Nonclinical Models.Targeting the N terminus for site-selective protein modification.Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase.Insights on the Structure, Molecular Weight, and Activity of an Antibacterial Protein-Polymer Hybrid.The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties.Solid Phase Stepwise Synthesis of Polyethylene Glycols.Targeting KCa1.1 channels with a scorpion venom peptide for the therapy of rat models of rheumatoid arthritis.IL-2 and Beyond in Cancer Immunotherapy.Characterization of a PEGylated protein therapeutic by ion exchange chromatography with on-line detection by native ESI MS and MS/MS.Aptamer Therapeutics in Cancer: Current and Future.Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.Disulfide conjugation chemistry: a mixed blessing for therapeutic drug delivery?Grafting challenging monomers from proteins using aqueous ICAR ATRP under bio-relevant conditionsPractical aspects of extended half-life products for the treatment of haemophiliaUtility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct modelPLGA-Based Nanoparticles in Cancer Treatment
P2860
Q28066686-48A30241-BF18-430A-97A2-F52D9D695F08Q33838927-B32718A3-A160-4CD0-93AF-8550C0C5EDA6Q33878021-A3922FF0-C84E-458B-913D-F458F0B62AA4Q38645927-8BEFA0C6-5058-40C5-BDC9-4622FD81E0B4Q38708465-3128A855-029B-4213-AA00-FE4EAF7893F3Q38838461-4AB9E321-F8B7-40DE-BD4B-965B142298D1Q38870681-1100DBF1-9529-4C49-9FCC-C4DB58AE55D4Q38972974-01BA2AB1-E516-4591-A353-DA817D464AEBQ38979811-9D69BE69-28D6-4627-9C25-BEE89A0E6A52Q39148639-2F4022EC-BBCF-4CB2-87E6-609DBC176219Q39234026-41AED7F7-C0BA-4C12-ACAF-BF9DDA1341E1Q40098238-A806B685-EFAE-4320-8729-A4F02E97E8ABQ41140550-A268DFD7-E988-4F6E-ACB7-CDB96FDC2029Q41196820-3635E7DB-DE59-4F2A-845F-29F7C35B5B04Q42369377-C9BDFEB2-2165-4423-A2A2-37B6B44CC884Q42508659-FCE8C9A4-C9E7-4BB9-A379-5D458A967445Q42635183-DEDDBF75-A92F-438B-B380-6F9BDD69EB3EQ46341302-557BA979-5498-49D7-9218-533029DD1BC7Q46463952-2673CCC4-2D4A-42F2-AF78-EFE48084DF3DQ47128548-73697011-DC95-4AA8-9359-F9BDA0A16CA4Q47176699-2810CB88-84EB-496C-BFE2-FB41CD58AC8EQ47596433-6D60C261-3539-4040-84B3-9B44828B8ED7Q47729137-C039B867-1BB3-4A91-BC7B-E820592D3CD9Q47753474-7BE0FE25-15BB-4532-80F3-37FB5667AE59Q48186975-702F91C5-C0D8-49A3-972D-FB042CF42962Q49915002-74A97120-8E27-4CF4-BA96-6B167C079B71Q50004232-3C861D48-5B1E-4A8C-B06E-8255AE6A5E22Q51268017-1BA660B0-BA4F-4BBC-9187-2C3E7E335C34Q52347485-562CCD48-37AF-43BE-8651-736C26336353Q52684506-785C0324-A9A6-4CF4-BF6F-5D45228D5E75Q52707854-0B96331B-9D1A-4297-B756-D4E93DEEABCFQ54173895-BD69AFF5-5C15-442C-9FC5-4E54B38B60A6Q54611176-FF5C24B3-493A-4B43-A392-D34DB5D1F4E6Q57367816-F83BA10F-5AF7-486F-8BFA-42E380CED553Q58761664-C89D70D7-76AF-461D-909C-158ADF919FABQ59136160-897CB2FC-41BB-4ED2-9379-628B798B75ECQ59137460-823B271F-E776-4FED-9070-E851F71C7FD6
P2860
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PEGylation of Biopharmaceutica ...... Information of Approved Drugs.
@en
type
label
PEGylation of Biopharmaceutica ...... Information of Approved Drugs.
@en
prefLabel
PEGylation of Biopharmaceutica ...... Information of Approved Drugs.
@en
P2093
P1476
PEGylation of Biopharmaceutica ...... Information of Approved Drugs.
@en
P2093
Freddy Schoetens
Inge A Ivens
Mary J Bossard
Peter L Turecek
P304
P356
10.1016/J.XPHS.2015.11.015
P407
P577
2016-02-01T00:00:00Z